Novo Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company that specializes in diabetes care and hormone replacement therapies. Founded in 1923, the company is known for its innovative insulin products and GLP-1 receptor agonists, such as Ozempic, which are used for managing diabetes and aiding in weight loss. Novo Nordisk has a strong commitment to research and development, particularly in the fields of diabetes, obesity, and hemophilia.
Born on Sep 07, 1923 (102 years old)
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Denmark | 1 | 6.00 | 0.11% | +0% | 5,792,202 | 6,129 | $350,000 | 370$ |
| Totals | 1 | 5,792,202 | 6,129 | $350,000 | 370$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Denmark:
Novo Nordisk is suing Eli Lilly for misleading marketing practices.
6
Thailand:
Novo Nordisk is referenced for its partnership with Hims & Hers Health Inc to enhance market presence.
7
Sweden:
Novo Nordisk is the company that manufactures Wegovy and applied for subsidies for specific patient groups.
5
Denmark:
Novo Nordisk's spokespersons shake their heads at the argument for lifestyle changes.
5
Denmark:
Novo Nordisk is taking legal action against Hims and Hers for producing a copy of their weight loss drug Wegovy.
6
Sweden:
Novo Nordisk fell 6.2 percent in New York after a significant drop in Copenhagen.
4
Sweden:
Novo Nordisk fell 6.2 percent in New York after a significant drop in Copenhagen.
4
United States:
The Trump administration recently negotiated a deal with Eli Lilly and Novo Nordisk to provide their weight loss drugs to Medicare at a discounted rate.
6
Romania:
Novo Nordisk is working on a similar experimental treatment recently acquired from China.
7
France:
Novo Nordisk was in competition with Pfizer to acquire Metsera but ultimately lost the bid.
4